These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 37057834

  • 1. Does "Low-Grade" Dedifferentiated Liposarcoma Exist? The Role of Mitotic Index in Separating Dedifferentiated Liposarcoma From Cellular Well-differentiated Liposarcoma.
    Graham DS, Qorbani A, Eckardt MA, Klingbeil KD, Chen LY, Chopra S, Eilber FC, Dry SM.
    Am J Surg Pathol; 2023 Jun 01; 47(6):649-660. PubMed ID: 37057834
    [Abstract] [Full Text] [Related]

  • 2. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
    Dantey K, Schoedel K, Yergiyev O, Bartlett D, Rao UNM.
    Hum Pathol; 2017 Aug 01; 66():86-92. PubMed ID: 28300575
    [Abstract] [Full Text] [Related]

  • 3. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
    Sharma AE, Dickson M, Singer S, Hameed MR, Agaram NP.
    Mod Pathol; 2024 Jun 01; 37(6):100494. PubMed ID: 38621503
    [Abstract] [Full Text] [Related]

  • 4. Influence of age and subtype in outcome of operable liposarcoma.
    Greto D, Saieva C, Loi M, Terziani F, Visani L, Garlatti P, Lo Russo M, Muntoni C, Becherini C, Topulli J, Campanacci D, Beltrami G, Scoccianti G, Muratori F, Bonomo P, Desideri I, Francolini G, Livi L.
    Radiol Med; 2019 Apr 01; 124(4):290-300. PubMed ID: 30421387
    [Abstract] [Full Text] [Related]

  • 5. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
    Lu J, Wood D, Ingley E, Koks S, Wong D.
    Mol Biol Rep; 2021 Apr 01; 48(4):3637-3647. PubMed ID: 33893924
    [Abstract] [Full Text] [Related]

  • 6. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF, Thierry S, Cabillic F, Lannes M, Burtin F, Henno S, Dugay F, Bouzillé G, Rioux-Leclercq N, Belaud-Rotureau MA, Stock N.
    Hum Pathol; 2017 Jan 01; 59():34-40. PubMed ID: 27597521
    [Abstract] [Full Text] [Related]

  • 7. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
    Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N.
    Cancer Med; 2023 Feb 01; 12(4):4282-4293. PubMed ID: 36151848
    [Abstract] [Full Text] [Related]

  • 8. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.
    Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP.
    J Am Coll Surg; 2014 Feb 01; 218(2):206-17. PubMed ID: 24315890
    [Abstract] [Full Text] [Related]

  • 9. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D, Van Gorp J, Speel EJ, Ferdinande L.
    Anticancer Res; 2015 Apr 01; 35(4):1835-42. PubMed ID: 25862836
    [Abstract] [Full Text] [Related]

  • 10. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
    Dang TN, Tiongco RP, Brown LM, Taylor JL, Lyons JM, Lau FH, Floyd ZE.
    BMC Cancer; 2022 Mar 21; 22(1):300. PubMed ID: 35313831
    [Abstract] [Full Text] [Related]

  • 11. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D.
    Lab Invest; 2011 Mar 21; 91(3):392-403. PubMed ID: 21060307
    [Abstract] [Full Text] [Related]

  • 12. What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities?
    Nakata E, Kunisada T, Hasei J, Nakahara R, Yanai H, Toji T, Inoue Ct H, Ozaki T.
    Clin Orthop Relat Res; 2020 Nov 21; 478(11):2550-2561. PubMed ID: 33112583
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcome of dedifferentiated liposarcoma in the extremities: A retrospective case series of 7 patients.
    Kito M, Yoshimura Y, Isobe K, Aoki K, Suzuki S, Tanaka A, Okamoto M, Sano K, Kato H.
    J Orthop Sci; 2016 Sep 21; 21(5):673-7. PubMed ID: 27317086
    [Abstract] [Full Text] [Related]

  • 14. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O, Wiśniewski P, Dansonka-Mieszkowska A, Grabowska-Kierył M, Olszewska K, Goryń T, Prochorec-Sobieszek M, Rutkowski P, Szumera-Ciećkiewicz A.
    Pathol Res Pract; 2021 Sep 21; 225():153555. PubMed ID: 34325315
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
    Yamashita K, Kohashi K, Yamada Y, Akatsuka S, Ikuta K, Nishida Y, Toyokuni S, Oda Y.
    Genes Chromosomes Cancer; 2021 Jan 21; 60(1):26-37. PubMed ID: 33111425
    [Abstract] [Full Text] [Related]

  • 16. Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study.
    Vos M, Boeve WC, van Ginhoven TM, Sleijfer S, Verhoef C, Grünhagen DJ.
    Eur J Surg Oncol; 2019 Dec 21; 45(12):2437-2442. PubMed ID: 31493984
    [Abstract] [Full Text] [Related]

  • 17. [Clinical value of fluorescence in situ hybridization with MDM2 and DDIT3 probe in diagnosis of liposarcoma].
    Wang W, Li X, Liu P, Dong Y.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr 18; 55(2):228-233. PubMed ID: 37042132
    [Abstract] [Full Text] [Related]

  • 18. Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).
    Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay JY, Strauss D, Rutkowski P, Ahuja N, Gonzalez R, Grignani G, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty VG, Canter RJ, Mullen JT, Pennacchioli E, van Houdt W, Swallow CJ, Schrage Y, Cardona K, Fiore M, Gronchi A, Bagaria SP.
    Ann Surg Oncol; 2021 Nov 18; 28(12):7854-7863. PubMed ID: 33907921
    [Abstract] [Full Text] [Related]

  • 19. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin.
    Fabbroni C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, Gronchi A, Dei Tos AP, Casali PG, Sanfilippo R.
    Cancers (Basel); 2021 Mar 22; 13(6):. PubMed ID: 33810165
    [Abstract] [Full Text] [Related]

  • 20. Detection of MDM2 gene amplification on tissue microarray-based Fluorescence In-Situ Hybridization (FISH) in well-differentiated and dedifferentiated liposarcomas, displaying a wide morphological spectrum: A validation study at a tertiary cancer referral centre.
    Rekhi B, Karnik N, Agrawal R, Shetty O, Patkar S.
    Indian J Pathol Microbiol; 2022 Mar 22; 65(1):65-75. PubMed ID: 35074968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.